198
Participants
Start Date
September 30, 2003
Primary Completion Date
September 30, 2008
Study Completion Date
June 30, 2009
Etoposide
50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
Gemcitabine
1000 mg/m2 IV, days 1 and 8, in regimen B
Irinotecan
1000 mg/m2 IV days 1 and 8 in regimen B
Paclitaxel
200 mg/m2 by 1-hour IV infusion, day 1, regimen A
Carboplatin
Area under the curve (AUC) 6.0 IV, day 1, regimen A
Consultants in Medical Oncology and Hematology, Drexel Hill
Reading Hospital Regional Cancer Center, West Reading
Cancer Outreach Associates, Abingdon
Spartanburg Regional Medical Center, Spartanburg
Wellstar Cancer Research, Marietta
Northeast Georgia Medical Center, Gainesville
Phoebe Cancer Center, Albany
Florida Hospital Cancer Institute, Orlando
Mercy Hospital Miami, Miami
Watson Clinic Center for Cancer Care and Research, Lakeland
Clearview Cancer Institute, Huntsville
Northeast Alabama Regional Medical Center, Anniston
Southern Cancer Center, Sacred Heart Heath System Medical Oncology Group, Mobile
Tennessee Oncology, PLLC, Nashville
Kingsport Hematology-Oncology, Kingsport
Thompson Cancer Survival Center, Knoxville
Jackson Oncology Associates, Jackson
Consultants in Blood Disorders and Cancer, Louisville
Graves-Gilbert Clinic, Bowling Green
Aultman Hospital, Canton
Oncology Hematology Care, Cincinnati
Oncology Hematology Associates of SW Indiana, Evansville
St. Joseph Mercy Oakland Hospital, Cancer Center, Pontiac
Grand Rapids Clinical Oncology Program, Grand Rapids
Montana Cancer Institute Foundation, Missoula
Methodist Cancer Center, Omaha
Terrebonne General Medical Center, Houma
Northeast Arkansas Clinic, Jonesboro
South Texas Oncology and Hematology, San Antonio
Tower Oncology, Beverly Hills
Mercy Hospital, Portland
Collaborators (1)
AstraZeneca
INDUSTRY
Pharmacia and Upjohn
INDUSTRY
Eli Lilly and Company
INDUSTRY
SCRI Development Innovations, LLC
OTHER